

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application.

**Listing of Claims:**

1 (Original). A method of delivering a heterologous nucleic acid to at least one muscle cell in a mammalian subject, comprising:

(a) providing at least one recombinant adeno-associated virus (rAAV) virion, said rAAV virion comprising an AAV-6 capsid and a heterologous nucleic acid operably linked to expression control elements; and

(b) administering said rAAV virions to said muscle cell, whereby expression of said heterologous nucleic acid provides for a therapeutic effect.

2 (Original). The method of claim 1, wherein said heterologous nucleic acid is a gene encoding a protein.

3 (Original). The method of claim 1, wherein said heterologous nucleic acid is an antisense RNA.

4 (Original). The method of claim 2, wherein said protein is a secreted protein.

5 (Original). The method of claim 4, wherein said secreted protein is selected from the group consisting of cytokines, growth factors, and differentiation factors.

6 (Original). The method of claim 2, wherein said protein is alpha1-antitrypsin or erythropoietin.

7 (Original). The method of claim 1, wherein said administering of said rAAV virions is by way of direct injection to said muscle cell of said mammalian subject.

8 (Original). The method of claim 7, wherein said muscle cell is a skeletal muscle cell.

9 (Original). The method of claim 1, wherein said administering of said rAAV virions is by way of administration to a vascular conduit of said mammalian subject.

10 (Original). The method of claim 9, wherein said vascular conduit is a vein.